Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther March 1 2018 17 (3) 589-589;

Review

  • Review
    Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
    Bayley A. Jones, Sooryanarayana Varambally and Rebecca C. Arend
    Mol Cancer Ther March 1 2018 17 (3) 591-602; DOI:10.1158/1535-7163.MCT-17-0437

Small Molecule Therapeutics

  • Small Molecule Therapeutics
    Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
    Paola Magnaghi, Barbara Salom, Liviana Cozzi, Nadia Amboldi, Dario Ballinari, Elena Tamborini, Fabio Gasparri, Alessia Montagnoli, Laura Raddrizzani, Alessio Somaschini, Roberta Bosotti, Christian Orrenius, Fabio Bozzi, Silvana Pilotti, Arturo Galvani, Josh Sommer, Silvia Stacchiotti and Antonella Isacchi
    Mol Cancer Ther March 1 2018 17 (3) 603-613; DOI:10.1158/1535-7163.MCT-17-0324

  • Small Molecule Therapeutics
    Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia
    Noelia Puente-Moncada, Paula Costales, Isaac Antolín, Luz-Elena Núñez, Patricia Oro, Maria Ana Hermosilla, Jhudit Pérez-Escuredo, Nicolás Ríos-Lombardía, Ana M. Sanchez-Sanchez, Elisa Luño, Carmen Rodríguez, Vanesa Martín and Francisco Morís
    Mol Cancer Ther March 1 2018 17 (3) 614-624; DOI:10.1158/1535-7163.MCT-17-0530

  • Small Molecule Therapeutics
    NEO212 Inhibits Migration and Invasion of Glioma Stem Cells
    Nagore I. Marín-Ramos, Thu Zan Thein, Hee-Yeon Cho, Stephen D. Swenson, Weijun Wang, Axel H. Schönthal, Thomas C. Chen and Florence M. Hofman
    Mol Cancer Ther March 1 2018 17 (3) 625-637; DOI:10.1158/1535-7163.MCT-17-0591

Large Molecule Therapeutics

  • Large Molecule Therapeutics | AuthorChoice
    An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer
    Sunil Bhakta, Lisa M. Crocker, Yvonne Chen, Meredith Hazen, Melissa M. Schutten, Dongwei Li, Coenraad Kuijl, Rachana Ohri, Fiona Zhong, Kirsten A. Poon, Mary Ann T. Go, Eric Cheng, Robert Piskol, Ron Firestein, Aimee Fourie-O'Donohue, Katherine R. Kozak, Helga Raab, Jo-Anne Hongo, Deepak Sampath, Mark S. Dennis, Richard H. Scheller, Paul Polakis and Jagath R. Junutula
    Mol Cancer Ther March 1 2018 17 (3) 638-649; DOI:10.1158/1535-7163.MCT-17-0813

  • Large Molecule Therapeutics | AuthorChoice
    A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)
    Michael L. Miller, Manami Shizuka, Alan Wilhelm, Paulin Salomon, Emily E. Reid, Leanne Lanieri, Surina Sikka, Erin K. Maloney, Lauren Harvey, Qifeng Qiu, Katie E. Archer, Chen Bai, Dilrukshi Vitharana, Luke Harris, Rajeeva Singh, Jose F. Ponte, Nicholas C. Yoder, Yelena Kovtun, Katharine C. Lai, Olga Ab, Jan Pinkas, Thomas A. Keating and Ravi V.J. Chari
    Mol Cancer Ther March 1 2018 17 (3) 650-660; DOI:10.1158/1535-7163.MCT-17-0940

  • Large Molecule Therapeutics
    Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycin–Antibody Conjugate
    Tadanobu Nagaya, Alexander P. Gorka, Roger R. Nani, Shuhei Okuyama, Fusa Ogata, Yasuhiro Maruoka, Peter L. Choyke, Martin J. Schnermann and Hisataka Kobayashi
    Mol Cancer Ther March 1 2018 17 (3) 661-670; DOI:10.1158/1535-7163.MCT-17-0851

  • Large Molecule Therapeutics
    Phase I Dose-Escalation Study of Anti–CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
    Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Jennifer J. Wheler, David S. Hong, Aung Naing, Gerald S. Falchook, Michelle A. Fanale, Maria E. Cabanillas and Filip Janku
    Mol Cancer Ther March 1 2018 17 (3) 671-676; DOI:10.1158/1535-7163.MCT-17-0673

  • Large Molecule Therapeutics
    Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates
    Donglu Zhang, Shang-Fan Yu, S. Cyrus Khojasteh, Yong Ma, Thomas H. Pillow, Jack D. Sadowsky, Dian Su, Katherine R. Kozak, Keyang Xu, Andrew G. Polson, Peter S. Dragovich and Cornelis E.C.A. Hop
    Mol Cancer Ther March 1 2018 17 (3) 677-685; DOI:10.1158/1535-7163.MCT-17-0697

Cancer Biology and Translational Studies

  • Cancer Biology and Translational Studies
    Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells
    Michael P. Plebanek, Debayan Bhaumik, Paul J. Bryce and C. Shad Thaxton
    Mol Cancer Ther March 1 2018 17 (3) 686-697; DOI:10.1158/1535-7163.MCT-17-0981

  • Cancer Biology and Translational Studies
    Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors
    Apurva K. Srivastava, Melinda G. Hollingshead, Jeevan Prasaad Govindharajulu, Joseph M. Covey, Dane Liston, Melanie A. Simpson, James O. Peggins, Donald P. Bottaro, John J. Wright, Robert J. Kinders, James H. Doroshow and Ralph E. Parchment
    Mol Cancer Ther March 1 2018 17 (3) 698-709; DOI:10.1158/1535-7163.MCT-17-0552

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
    A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma
    Conor E. Steuer, Christopher C. Griffith, Sreenivas Nannapaneni, Mihir R. Patel, Yuan Liu, Kelly R. Magliocca, Mark W. El-Deiry, Cynthia Cohen, Taofeek K. Owonikoko, Dong M. Shin, Zhuo G. Chen and Nabil F. Saba
    Mol Cancer Ther March 1 2018 17 (3) 710-716; DOI:10.1158/1535-7163.MCT-17-0504

Back to top
PreviousNext
Molecular Cancer Therapeutics: 17 (3)
March 2018
Volume 17, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Issue Highlights

  • A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)
  • Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
  • Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
  • An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Jump to

  • Highlights
  • Review
  • Small Molecule Therapeutics
  • Large Molecule Therapeutics
  • Cancer Biology and Translational Studies
  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement